NASDAQ:EDIT

Editas Medicine Stock Insider Trading

Healthcare > Biotechnology

Buy EDIT

*Your capital is at risk

$2.81

-0.0700 (-2.43%)

At Close: Aug 10, 2026

Editas Medicine Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 65.24. In total, the insiders bought 6.36M and sold 211.57K EDIT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	65.24
● Buy	6.36M shares
● Sell	211.57K shares
51% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Jun 03, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 65.24. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	26 850 Value: $425.0K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	6 091 Value: $53.1K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	17 220 Value: $170.8K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	145 548 Value: $250.3K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	145 548 Value: $250.3K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	17 220 Value: $170.8K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	6 091 Value: $53.1K
Mar 28, 2025 Buy	Stock Option (right to buy)	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	26 850 Value: $425.0K
Mar 28, 2025 Buy	Common Stock	Parison Amy SVP, Chief Financial Officer	C-Suite Officer	0 Value: $0
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Lucera Erick EVP, Chief Financial Officer	C-Suite Officer	275 100 Value: $473.2K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Lucera Erick EVP, Chief Financial Officer	C-Suite Officer	70 000 Value: $120.4K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	O'neill Gilmore Neil CEO	CEO / President	828 000 Value: $1.42M
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	O'neill Gilmore Neil CEO	CEO / President	175 000 Value: $301.0K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Burkly Linda EVP, Chief Scientific Officer	Officer	275 100 Value: $473.2K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Burkly Linda EVP, Chief Scientific Officer	Officer	70 000 Value: $120.4K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Burkly Linda EVP, Chief Scientific Officer	Officer	70 000 Value: $120.4K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Burkly Linda EVP, Chief Scientific Officer	Officer	275 100 Value: $473.2K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	O'neill Gilmore Neil CEO	CEO / President	175 000 Value: $301.0K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	O'neill Gilmore Neil CEO	CEO / President	828 000 Value: $1.42M
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Lucera Erick EVP, Chief Financial Officer	C-Suite Officer	70 000 Value: $120.4K
Mar 08, 2025 Buy	Stock Option (right to buy) A-Award	Lucera Erick EVP, Chief Financial Officer	C-Suite Officer	275 100 Value: $473.2K
Mar 04, 2025 Sell	Common Stock S-Sale	Lucera Erick EVP, Chief Financial Officer	C-Suite Officer	4 109 Value: $7K
Mar 04, 2025 Sell	Common Stock S-Sale	O'neill Gilmore Neil CEO	CEO / President	16 632 Value: $28.5K
Mar 04, 2025 Sell	Common Stock S-Sale	Burkly Linda EVP, Chief Scientific Officer	Officer	2 891 Value: $5K
Mar 04, 2025 Sell	Common Stock S-Sale	Burkly Linda EVP, Chief Scientific Officer	Officer	2 891 Value: $5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT EDITAS MEDICINE, INC

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...

Read Full Profile Here